Citadel Advisors LLC Buys New Holdings in Rallybio Corporation $RLYB

Key Points

• Citadel Advisors acquired 72,200 Rallybio shares worth approximately $1.16 million, giving it a 1.36% stake. Institutional investors collectively own 90.34% of the company.
• Rallybio reported a quarterly loss of $1.09 per share, beating analysts’ expected loss of $1.28, but continued to post weak profitability metrics, including a negative net margin of 911.07%.
• RLYB shares opened at $16.75, near their 52-week high of $17.57. Analyst sentiment improved, with upgrades from “sell” to “hold” and “hold” to “buy,” though the overall consensus rating remains “Hold.”

Citadel Advisors LLC bought a new position in Rallybio Corporation (NASDAQ:RLYB - Free Report) in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 72,200 shares of the company's stock, valued at approximately $1,155,000. Citadel Advisors LLC owned 1.36% of Rallybio at the end of the most recent reporting period.

A number of other institutional investors have also recently bought and sold shares of the business. ADAR1 Capital Management LLC raised its stake in shares of Rallybio by 4,411.1% in the 2nd quarter. ADAR1 Capital Management LLC now owns 926,352 shares of the company's stock valued at $14,822,000 after buying an additional 905,817 shares in the last quarter. Renaissance Technologies LLC boosted its position in shares of Rallybio by 16.9% during the 4th quarter. Renaissance Technologies LLC now owns 835,692 shares of the company's stock valued at $573,000 after acquiring an additional 120,892 shares in the last quarter. Susquehanna International Group LLP boosted its position in shares of Rallybio by 485.9% during the 3rd quarter. Susquehanna International Group LLP now owns 136,294 shares of the company's stock valued at $68,000 after acquiring an additional 113,031 shares in the last quarter. XTX Topco Ltd increased its stake in Rallybio by 64.6% in the fourth quarter. XTX Topco Ltd now owns 97,313 shares of the company's stock valued at $67,000 after acquiring an additional 38,205 shares during the period. Finally, BlackRock Inc. increased its stake in Rallybio by 73.5% in the second quarter. BlackRock Inc. now owns 30,332 shares of the company's stock valued at $485,000 after acquiring an additional 12,846 shares during the period. Institutional investors and hedge funds own 90.34% of the company's stock.

Rallybio Price Performance

RLYB stock opened at $16.75 on Friday. The business has a fifty day moving average price of $16.44 and a 200 day moving average price of $13.45. Rallybio Corporation has a fifty-two week low of $3.67 and a fifty-two week high of $17.57. The stock has a market capitalization of $88.94 million, a price-to-earnings ratio of -3.86 and a beta of -0.85.

Rallybio (NASDAQ:RLYB - Get Free Report) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($1.09) EPS for the quarter, topping analysts' consensus estimates of ($1.28) by $0.19. Rallybio had a negative return on equity of 40.53% and a negative net margin of 911.07%.

Analyst Ratings Changes

RLYB has been the subject of a number of analyst reports. Weiss Ratings upgraded shares of Rallybio from a "sell (d-)" rating to a "hold (c-)" rating in a research note on Wednesday, August 19th. Wall Street Zen upgraded Rallybio from a "hold" rating to a "buy" rating in a research note on Saturday, August 15th. One investment analyst has rated the stock with a Hold rating, According to MarketBeat, the stock has a consensus rating of "Hold".

Rallybio Profile

Rallybio Therapeutics, Inc NASDAQ: RLYB is a clinical‐stage biotechnology company focused on developing and commercializing therapies for people living with rare genetic diseases. The company's scientific approach leverages diverse modalities—including monoclonal antibodies, small molecules and enzyme replacement—to address high‐unmet‐need conditions in areas such as immunodeficiency, metabolic disorders and dermatologic diseases. Rallybio's pipeline is designed to advance through registrational clinical trials with the goal of delivering first‐in‐class or best‐in‐class therapies to patients who currently have limited or no approved treatment options.

Among Rallybio's lead programs is RBX‐100, an investigational therapy for congenital athymia, a rare pediatric immunodeficiency.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.